Best GLP-1 for Weight Loss: Approved Options Ranked for 2026

Measured by average weight loss in clinical trials, the most effective FDA-approved GLP-1 medicine for weight loss is Zepbound (tirzepatide): adults without diabetes lost an average of 20.9% of their body weight on the 15 mg dose over 72 weeks, and it beat Wegovy 2.4 mg in the only head-to-head trial, 20.2% to 13.7%. High-dose Wegovy (7.2 mg) comes next at about 18.7%, followed by standard Wegovy injections, the Wegovy pill, the Foundayo pill and Saxenda.

That ranking answers "which causes the most weight loss on average." It does not answer "which is best for me," because the right choice also depends on your other health conditions, whether you would rather take a pill, what your insurance covers and what you can afford to stay on. This guide ranks the approved options, then matches them to common situations. It is general information; a prescriber who knows your history should make the call with you.

FDA-approved GLP-1 weight-loss medicines, ranked by average weight loss

Medicine	Ingredient	How taken	Average weight loss in its main trial (adults without diabetes)	Placebo in same trial	Self-pay price per month, Oct. 2026
Zepbound 15 mg	Tirzepatide	Weekly injection	20.9% at 72 weeks	3.1%	$449 with on-time refills
Zepbound 10 mg	Tirzepatide	Weekly injection	19.5% at 72 weeks	3.1%	$449 with on-time refills
Wegovy HD 7.2 mg	Semaglutide	Weekly injection	18.7% at 72 weeks	3.9%	$399
Zepbound 5 mg	Tirzepatide	Weekly injection	15.0% at 72 weeks	3.1%	$399
Wegovy 2.4 mg	Semaglutide	Weekly injection	14.9% at 68 weeks	2.4%	$349
Wegovy tablets 25 mg	Semaglutide	Daily pill, empty stomach	13.6% at 64 weeks	2.2%	$299
Foundayo 17.2 mg	Orforglipron	Daily pill, any time	11.1% at 72 weeks	2.1%	$349
Saxenda 3 mg	Liraglutide	Daily injection	8.0% at 56 weeks	2.6%	Varies; generic liraglutide exists

Weight-loss figures come from the FDA labels and the published pivotal trials (SURMOUNT-1, STEP UP, STEP 1, OASIS 4, ATTAIN-1 and SCALE). Prices are the manufacturers' self-pay prices checked October 14, 2026.

How to read this table

• Most rows come from separate trials. Different years, different participants, different lengths. Only Zepbound and Wegovy 2.4 mg have been compared directly (SURMOUNT-5), and only Wegovy 7.2 mg and 2.4 mg were tested in the same study (STEP UP).
• These are averages. In SURMOUNT-1, about 9% of people on Zepbound 15 mg lost less than 5% of their weight, while 57% lost 20% or more. In STEP 1, about 16% on Wegovy lost less than 5%.
• Everyone in these trials also got diet and activity counseling. The labels approve these drugs in combination with a reduced-calorie diet and increased physical activity, not instead of them.
• People with type 2 diabetes lose less. In the labels, average loss was 12.8% to 14.7% on Zepbound 10 to 15 mg, 9.6% on Wegovy 2.4 mg and 9.6% on Foundayo 17.2 mg.

Who qualifies for a GLP-1 for weight loss

The FDA-approved criteria are the same across Zepbound, Wegovy and Foundayo for adults:

• a body mass index (BMI) of 30 or higher (obesity), or
• a BMI of 27 or higher (overweight) with at least one weight-related condition, such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea or cardiovascular disease.

Wegovy injection and Saxenda are also approved for adolescents 12 and older with obesity. Insurers often add their own requirements on top, such as documented participation in a weight-management program.

Who should not take any of them: people with a personal or family history of medullary thyroid carcinoma, people with Multiple Endocrine Neoplasia syndrome type 2, anyone who has had a serious allergic reaction to the drug, and anyone who is pregnant. All carry a boxed warning about thyroid C-cell tumors seen in rodent studies. Tell your prescriber about any history of pancreatitis, gallbladder disease, kidney disease, diabetic eye disease or severe stomach problems.

The best GLP-1 by situation

For the most weight loss: Zepbound

Tirzepatide has the strongest numbers and the only head-to-head win. In SURMOUNT-5, 751 adults with obesity were assigned to the highest tolerated dose of Zepbound or Wegovy for 72 weeks; average loss was 20.2% versus 13.7%, about 50 pounds versus 33. Nearly a third of the Zepbound group lost at least a quarter of their body weight. If 2.4 mg of Wegovy has not been enough, the 7.2 mg dose approved in March 2026 is the semaglutide answer, at the cost of more side effects. Details in Wegovy vs Zepbound.

For people with heart disease: Wegovy

Wegovy is the only weight-management drug with an FDA indication to lower the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease and obesity or overweight. The SELECT trial of 17,604 people without diabetes found a 20% relative reduction (6.5% versus 8.0% with placebo over about 40 months). The Wegovy tablet carries the same indication. Tirzepatide's cardiovascular approval, under the Mounjaro name, applies to adults with type 2 diabetes.

For obstructive sleep apnea: Zepbound

Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity, at 10 or 15 mg. In its trials, breathing interruptions fell by 25 to 29 events per hour, compared with about 5 on placebo.

For type 2 diabetes: usually the diabetes brands

If you have type 2 diabetes, the same molecules are prescribed as Mounjaro (tirzepatide) or Ozempic (semaglutide), which insurers cover far more readily. In SURPASS-2, Mounjaro lowered A1C by 2.0 to 2.3 points and weight by 7.6 to 11.2 kg, versus 1.9 points and 5.7 kg on Ozempic 1 mg. For cardiovascular benefit in diabetes, both now have indications; for chronic kidney disease in diabetes, Ozempic is the one with an approved kidney indication. See Ozempic vs Mounjaro.

For fatty liver disease with fibrosis (MASH): Wegovy

Wegovy injection has accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

For people who do not want injections: Wegovy tablets or Foundayo

Two daily pills are approved for weight management. Wegovy tablets (semaglutide 25 mg) produced 13.6% average loss at 64 weeks but must be taken on an empty stomach with a sip of water, 30 minutes before anything else. Foundayo (orforglipron) produced 11.1% at 72 weeks and can be taken at any time, with or without food. Full comparison: Foundayo vs the Wegovy pill.

For the lowest out-of-pocket cost

For cash payers, the pills start at $149 a month. At maintenance doses, Wegovy tablets ($299), Foundayo ($299 to $349) and the Wegovy pen ($349) undercut Zepbound ($399 to $449 with timely refills). Saxenda's ingredient, liraglutide, is the only one in this class with generic versions on the U.S. market, though it requires a daily injection and produces the least weight loss of the group. Every route is priced in GLP-1 cost without insurance.

For people on Medicare

From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge covers Wegovy (injection or tablets), the Zepbound KwikPen and Foundayo for a $50 monthly copay for Part D enrollees who meet BMI and health criteria, such as a BMI of 35 or higher, or 27 or higher with prediabetes or a previous heart attack or stroke. Since all three cost the same $50, the choice can rest on medical fit.

For teenagers

Wegovy injection (from age 12) and Saxenda (from age 12) are the approved options. Zepbound, Foundayo and the Wegovy tablet are approved for adults only.

Is one GLP-1 best for women, men, PCOS or menopause?

Many searches ask for the best GLP-1 for a particular group. The honest answer is that the FDA has not approved any of these medicines for a specific sex, for polycystic ovary syndrome, for menopause-related weight gain or for "inflammation," and no head-to-head trial has shown that one drug is better than another in those groups.

• PCOS. No GLP-1 drug is approved to treat PCOS. Many people with PCOS qualify for treatment through the standard BMI criteria, and weight loss can improve some features of the condition. Which drug to use is an individual decision with your clinician.
• Women of childbearing age. None of these drugs should be used in pregnancy. Wegovy's label says to stop at least two months before a planned pregnancy. Zepbound's and Foundayo's labels advise people on birth control pills to switch to a non-oral method or add a barrier method for about four weeks after starting and after each dose increase.
• Perimenopause and menopause. The trials enrolled large numbers of women in midlife; roughly two-thirds to three-quarters of participants in the main obesity trials were women. Eligibility is by BMI, not by menopausal status.
• Men. Same drugs, same doses, same criteria.
• Older adults. Weight lost on these medicines includes some muscle as well as fat. For older adults in particular, clinicians commonly emphasize adequate protein and resistance exercise, and watch for dehydration from stomach side effects, which can strain the kidneys.
• Inflammation. Markers such as C-reactive protein fall with weight loss on these drugs, but none is approved to treat an inflammatory disease.

Side effects: what to expect from any of them

The whole class shares a pattern: nausea, diarrhea, constipation and vomiting, clustered around dose increases and usually easing with time.

Side effect	Zepbound 15 mg	Wegovy 2.4 mg	Wegovy 7.2 mg	Foundayo 17.2 mg
Nausea	28%	44%	39%	35%
Diarrhea	23%	30%	not in its table	25%
Vomiting	13%	24%	22%	24%
Constipation	11%	24%	20%	24%
Hair loss	5%	3%	6%	5%

Rates are from each product's FDA label and come from different trials, so they are not a ranking. Wegovy 7.2 mg also caused a skin tingling or sensitivity reaction (dysesthesia) in 22% of people. Serious but uncommon risks across the class include pancreatitis, gallbladder disease, kidney injury from dehydration and severe gastrointestinal reactions.

Contact your prescriber for vomiting or diarrhea that will not stop. Go to an emergency room for severe abdominal pain that does not ease, or for trouble breathing or swelling of the face or throat.

What is not a GLP-1 medicine

Search results for "best GLP-1" are crowded with products that are not GLP-1 drugs at all.

• There is no over-the-counter GLP-1. Every GLP-1 receptor agonist requires a prescription.
• "GLP-1 supplements," "GLP-1 boosters" and probiotics typically contain fiber, berberine, chromium or plant extracts. They are dietary supplements. The FDA does not review them for effectiveness, and none has shown weight loss comparable to the medicines above.
• "GLP-1 patches" sold online are in the same category; they do not deliver semaglutide or tirzepatide. Our guide to GLP-1 patches covers what is in them.
• Compounded semaglutide or tirzepatide is a prescription product but is not FDA-approved, and the FDA moved in 2026 to tighten limits on it.
• Retatrutide, an experimental Lilly drug that acts on three receptors, had not been approved by the FDA when this guide was written in October 2026. Products sold online under that name are unapproved.
• Ozempic and Mounjaro are real GLP-1-class medicines, but they are approved for type 2 diabetes, not weight loss. Their weight-management versions are Wegovy and Zepbound. See Ozempic vs Wegovy and Mounjaro vs Zepbound.

How to choose: a step-by-step approach

1. Confirm you meet the criteria. Calculate your BMI and list any weight-related conditions with your clinician.
2. List conditions that point to a specific drug. Cardiovascular disease or MASH (Wegovy), sleep apnea (Zepbound), type 2 diabetes (Mounjaro or Ozempic), chronic kidney disease with diabetes (Ozempic).
3. Rule out contraindications. Family history of medullary thyroid cancer or MEN 2, pregnancy plans, past pancreatitis.
4. Decide between pill and injection. A weekly shot generally produces more weight loss; a daily pill avoids needles and refrigeration.
5. Check coverage. Your plan's formulary may cover one drug and exclude the rest. On Medicare, ask about the GLP-1 Bridge.
6. Price the maintenance dose for a year if you will pay cash.
7. Review your other medicines, especially birth control pills, insulin and sulfonylureas.
8. Set a review point. If you have not lost a meaningful amount, often defined by insurers as about 5%, after several months at a maintenance dose, discuss a dose change or a different drug. Switching is covered in switching between semaglutide and tirzepatide.

How long you need to take it

Obesity is treated as a chronic condition, and the labels describe these medicines as long-term treatment. The withdrawal studies explain why. In the STEP 1 extension, people who stopped semaglutide 2.4 mg after 68 weeks regained about two-thirds of the weight they had lost within a year. In SURMOUNT-4, people who had lost about 21% on tirzepatide and were then switched to placebo regained 14% of their body weight over the next year, while those who continued lost a further 5.5%.

That makes staying power part of "best." A drug you can tolerate, obtain reliably and afford for years will usually serve you better than a more potent one you have to stop after a few months. For the molecule-level comparison behind this ranking, see semaglutide vs tirzepatide; for the pair that started the conversation, Zepbound vs Ozempic.